Synageva BioPharma (GEVA)

[surf1944]

7:05AM Synageva Biopharma announces publication of Late onset LAL deficiency literature review in the Journal of Hepatology (GEVA) 54.56 : Co announces the publication of an article entitled, "Cholesteryl Ester Storage Disease: Review of the Findings in 135 Reported Patients with an Under-Diagnosed Disease" in the online version and an upcoming print edition of the Journal of Hepatology. Co indicates the literature review underscores the "understanding that late onset LAL Deficiency, or CESD, is a progressive disease with severe liver and cardiovascular complications which can occur as early as the first and second decade of life...With the global ARISE Phase 3 trial of sebelipase alfa now underway in children and adults with LAL Deficiency, it is important that we continue to raise awareness of this underappreciated cause of cirrhosis and accelerated atherosclerosis."